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Purpose: The objective of this study was to evaluate the potential of prepared chitosan
-plasmid DNA nanoparticles in transferring the exogenous gene into human bone
marrow-derived mesenchymal stem cells. Methods: Chitosan/pDNA nanoparticles
were synthesized through the complex coacervation method using 18, 50 and 136
KD chitosan and pTracer-CMV2 plasmid containing Green Fluorescent Protein
(GFP) gene. In this regard several concentrations of chitosan solutions (0.05%, 0.1%,
0.5% and 1%) were used. To examine the complexation, samples were run through
an agarose gel. The size and zeta potential of nanoparticles were measured by Nano-
sizer. Scanning electron microscopy (SEM) imaging was used to observe the
morphology of nanoparticles. MSCs were prepared from human bone marrow and
transfected with chitosan/pDNA nanoparticles. The cultures transfected by lipofect-
amine2000 was taken as the control. Cell viability and transfection efficiency were
determined by MTT assay and flow cytometric analysis respectively. RESULTS: The
smallest size of complexes was obtained using 50KD chitosan (about 50nm) and the
highest zeta potential was with 136 KD chitosan (29.61mV). The best transfection
rate (18.43%) was achieved with 0.1% concentration of 18KD chitosan nanoparticles.
commercial lipofectamine transfected 40.57% of cells. MTT assay indicated an average
of 95.5% cell viability for 0.1% concentration of 18KD (chitosan compared with about
60% of Lipofectamine2000. Conclusions: Nanoparticles produced by 18KD chitosan at
0.1% concentration and pDNA would be a promising gene delivery system to human
marrow derived MSCs. Although transfection efficiency of such nanoparticles is lower
than that of Lipofectamine2000 but they comparatively possess less cytotoxic effects.
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A 53 year old multiparous woman with a hepatic mass was found to have AML. She
proceeded to induction chemotherapy resulting in complete remission by day 28.
Between cytarabine consolidation cycles, she received 3 TACE procedures for
presumed hepatocellular carcinoma. During first cycle, she developed platelet refrac-
toriness with no platelet increment one hour post transfusion. Testing confirmed the
presence of an HLA antibody. HLA matched platelet transfusions did not give a satis-
factory platelet increment. The decision was made to harvest and cryopreserve her
platelets, then reinfuse post chemotherapy.
The patient was scheduled to have plateletpheresis with a goal of 10 x 1011platelets to
be harvested and cryopreserved, allowing for 4 infusions as support over the nadir
post-chemotherapy. This was to be repeated to support the final round of
chemotherapy.
Collections: Once platelet count reachedO150, 4 collections were performed over
2.5 months yielding between 3.1 to 5.5 x 1011 platelets per harvest, irradiated at
25Gy, and cryopreserved in 5% DMSO using a controlled rate freezer. Studies on
her post-thaw platelets using PRP impedance indicated a 50% reduction in function-
ality compared with fresh platelets. Infusions: Four infusions were performed 11-20
days post consolidation 2 chemotherapy and three infusions 11-19 days post consol-
idation 3. No adverse reactions were reported. Platelet counts increased typically
from 11-29 (1.6 to 2.6 fold) within 24 hours of infusion. HLA matched platelets
gave no increase (pre-infusion count of 8, to post of 9, within 24 hours). There
were no clinically significant bleeding complications and she was able to finish her
scheduled rounds of chemotherapy. Conclusions: We have presented a case study
requiring harvest, cryopreservation and infusion of autologous platelets. Incorpo-
rating archived platelet protocols into current practices was easily and safely
achieved by the BMT laboratory. The methodology, equipment and processes
involved required little change from the traditional role of progenitor cell work
and this can safely extend the services offered by BMT laboratories with minimal
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Background: Lifelong haematopoiesis is mediated by haematopoietic stem cells
(HSCs) that give rise to all blood lineages. Long-term quiescent HSCs localise to
the interface between bone and bone marrow (B-BM). This anatomical juxtaposition
belies a functional relationship between bone metabolism and haematopoiesis. The
mature B-BM interface is a complex structure composed of intricate networks con-
necting cells, extracellular matrix, and growth factors. This complexity renders inves-
tigation of the component parts of the B-BM interface extremely difficult. Aim: This
study uses a unique model to investigate the early spatial and temporal events leading
to B-BM formation. Methods: Rat acellular demineralised bone matrix (DBM) was
implanted intermuscularly into the hind-limbs of nude mice, and explanted between
days 2-28. The resultant ectopic nodules were subjected to macroscopic, histological
and morphometric analyses (microCT scanning), gene expression studies and colony-
forming unit (CFU) assays. Results: The progressive increase in vascularity and
hardness of the nodules was reflected in their corresponding histological analyses.
Neovascularisation was an early event and appears to be essential for cellular repo-
pulation of the DBM. MicroCT imaging of explanted nodules first detected X-ray
dense areas by day 10. This preceded the appearance of haematopoietic progenitors
evident first on day 14 (CFU assays). The same types of CFUs were cultured from the
corresponding long-bone marrow. DBM remodelling resulted in mature nodules con-
sisting of newly formed bone (with the presence of osteoblasts, lining cells, osteo-
cytes and osteoclasts) encompassing a centralised marrow cavity; which was
confirmed histologically. Conclusion: Collectively, these findings suggest that
bone is integral to, and precedes the development of marrow. On-going studies
will determine critical changes in gene expression between days 7-14 that may be
associated with bone marrow development. The use of this unique ectopic bone
formation model to study the genesis of haematopoiesis may give us specific insights
into critical parameters that can influence microenvironmental cues for HSCs.P1163 - P18INK4C IS AN UNIQUE TARGET FOR HEMATOPOIETIC STEM
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The G1-phase of cell cycle is a critical window in which stem cell self-renewal may
be balanced with other fate choices. The cyclin-dependent kinase inhibitors (CKIs),
including p15, p16, p18, p19, p21, p27 and p57, have been reported to be involved in
the regulation of stem cells especially the hematopoietic stem cells (HSCs). Among
all the CKIs examined in HSCs, p18 and p27 were shown to have inhibitory effects
on HSC self-renewal or repopulation in mice. In this study, we show that p18 is
a more potent inhibitor for HSC self-renewal than p27 in vivo. Absence of p18 al-
lowed HSCs to be expanded and maintained in a long-term culture system for
more than 15 weeks. Surprisingly, overall cycling of hematopoietic cells was not
increased in the absence of p18. Instead, a favored outcome of self-renewal after
HSC division was indicated by single cell analyses. To target p18 pharmacologically,
we have designed a number of p18 small molecule inhibitors via in silico-screening
and validated them by functional assays. Importantly, the identified lead compounds
were able to specifically expand HSCs in vitro. Thus, these novel p18 small molecule
inhibitors offer valuable chemical probes for dissecting the signaling pathways of
self-renewal of tissue stem cells, and serve as important lead compounds to further
develop more effective agents for therapeutic stem cell expansion.
